Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

被引:13
|
作者
Kovac, Martina [1 ,5 ]
Kostanyan, Lusine [2 ]
Mesaros, Narcisa [1 ]
Kuriyakose, Sherine [3 ]
Varman, Meera [4 ]
机构
[1] GSK, Vaccines, Wavre, Belgium
[2] XPE Pharma & Sci, Wavre, Belgium
[3] GSK Vaccines, Bangalore, Karnataka, India
[4] Creighton Univ, Pediat Infect Dis, Omaha, NE 68178 USA
[5] GSK, Rockville, MD USA
关键词
decennial booster; diphtheria; pertussis; tetanus; vaccination; ADVISORY-COMMITTEE; ADVERSE REACTIONS; WHOLE-CELL; IMMUNITY; ADULTS; ASSAY; RECOMMENDATIONS; EPIDEMIOLOGY; IMMUNIZATION; PREVENTION;
D O I
10.1080/21645515.2018.1460292
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Pertussis is a highly contagious disease, for which periodic peaks in incidence and an increasing number of outbreaks have been observed over the last decades. The reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine (Tdap) can be used to boost individuals aged >= 10 years, vaccinated in infancy with a diphtheria-tetanus-acellular pertussis vaccine (DTaP), to reduce pertussis morbidity and maintain protection against diphtheria and tetanus throughout adolescence and adulthood. This phase III, open-label, non-randomized, multicenter follow-up study (NCT01738477) enrolled 19-30-year-old participants from the United States who had received booster vaccination 10 years earlier with either Tdap (Tdap group) or Td (Td group). In total, 128 (Tdap group) and 37 (Td group) participants received Tdap vaccination. After administration of Tdap, all participants were seroprotected (antibody concentrations >= 0.1 international units [IU]/ml) against diphtheria and tetanus. Immune responses to a second Tdap dose in the Tdap group were shown to be non-inferior to responses elicited by a first Tdap dose in the Td group for diphtheria and tetanus and to a 3-dose DTaP vaccination during infancy for pertussis antigens (primary objectives). Post-booster vaccination, all participants in both groups had antibody concentrations above assay cut-offs and antibody geometric mean concentrations increased by 3.8-15.5-fold compared to prebooster levels for all antigens. The incidence of adverse events was similar in the Td (80.6%) and Tdap (85.6%) groups (no serious adverse events reported). A Tdap dose administered after previous Td or Tdap vaccination was shown to be immunogenic and well-tolerated in young adults, supporting repeated vaccination with Tdap at 10-year intervals.
引用
收藏
页码:1977 / 1986
页数:10
相关论文
共 23 条
  • [1] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults
    Brandon, Donald
    Kimmel, Murray
    Kuriyakose, Sherine O.
    Kostanyan, Lusine
    Mesaros, Narcisa
    [J]. VACCINE, 2018, 36 (42) : 6325 - 6333
  • [2] Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study
    Asatryan, Asmik
    Meyer, Nadia
    Scherbakov, Michael
    Romanenko, Victor
    Osipova, Irina
    Galustyan, Anna
    Shamsheva, Olga
    Latysheva, Tatiana
    Myasnikova, Tatyana
    Baudson, Nathalie
    Dodet, Monique
    Xavier, Stebin
    Harrington, Lauriane
    Kuznetsova, Anastasia
    Campora, Laura
    Van den Steen, Peter
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 723 - 730
  • [3] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults (vol 36, pg 6325, 2018)
    Brandon, Donald
    Kimmel, Murray
    Kuriyakose, Sherine O.
    Kostanyan, Lusine
    Mesaros, Narcisa
    [J]. VACCINE, 2020, 38 (12) : 2746 - 2747
  • [4] Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age
    Rodrigo Vergara
    Miguel Tregnaghi
    José Ussher
    Sofía Navarro
    Ricardo Rüttimann
    Marcela Potin
    Joanne Wolter
    Lode Schuerman
    [J]. European Journal of Pediatrics, 2005, 164 : 377 - 382
  • [5] Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age
    Vergara, R
    Tregnaghi, M
    Ussher, J
    Navarro, S
    Rüttimann, R
    Potin, M
    Wolter, J
    Schuerman, L
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2005, 164 (06) : 377 - 382
  • [6] Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults
    Kovac, Martina
    Rathi, Niraj
    Kuriyakose, Sherine
    Hardt, Karin
    Schwarz, Tino F.
    [J]. VACCINE, 2015, 33 (22) : 2594 - 2601
  • [7] Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®)A Review of its Use as a Single-Dose Booster Immunization in Individuals Aged 10–64 Years in the US
    Greg L. Plosker
    [J]. BioDrugs, 2009, 23 : 253 - 267
  • [8] Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®) A Review of its Use as a Single-Dose Booster Immunization in Individuals Aged 10-64 Years in the US
    Plosker, Greg L.
    [J]. BIODRUGS, 2009, 23 (04) : 253 - 267
  • [9] Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose
    Halperin, Scott A.
    Donovan, Catherine
    Marshall, Gary S.
    Pool, Vitali
    Decker, Michael D.
    Johnson, David R.
    Greenberg, David P.
    Bader, Gerald
    Weisman, Stuart
    Chauhan, Ambaram
    Bromberg, Kenneth
    McGuire, Michael
    Kabongo, Martin L.
    Hall, Matthew
    Weiner, Leonard
    Silas, Peter
    Brune, Daniel
    Craig, Tim
    Michaels, Marion
    Anderson, Edwin
    Keathley, Susan
    Rouse, Kevin
    Leader, Joseph
    Helman, Laura
    Andrews, Wilson
    Bernstein, David
    Middleton, Randall
    Ghosh, Mahashweta
    Mitchell, Douglas
    Senders, Shelly
    Wyszomierski, David
    Allison, David
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2019, 8 (02) : 105 - 114
  • [10] Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age
    Dagan, R
    Igbaria, K
    Piglansky, L
    Van Brusteghem, F
    Melot, V
    Kaufhold, A
    [J]. VACCINE, 1999, 17 (20-21) : 2620 - 2627